A Non-interventional Biomarker Study in Patients With Non-Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Tumour Histology Eligible for Treatment With Vargatef® According to the Approved Label.
Phase of Trial: Phase IV
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Nintedanib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms LUME BioNIS
- Sponsors Boehringer Ingelheim
- 19 Sep 2017 Planned End Date changed from 15 Nov 2020 to 1 Nov 2021.
- 19 Sep 2017 Planned primary completion date changed from 15 Apr 2020 to 1 Apr 2021.
- 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress